Non-Small Cell Lung Cancer
Resource Center

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and begins when abnormal cells in the lungs grow out of control. Tumors can form in the lung tissue or airways and may spread to other parts of the body if not detected early. Several subtypes of NSCLC exist, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

Taiho Oncology Logo

What is Non-Small Cell Lung Cancer (NSCLC)?

Non-small cell lung cancer (NSCLC) is the most frequently diagnosed form of lung cancer, representing the majority of cases. It develops when abnormal cells in the lung tissue proliferate in an uncontrolled manner and form tumors within the lungs or associated airways. These malignancies may arise in different regions of the lung, including the bronchi, bronchioles, or alveoli, and can affect either lung.

Compared with small cell lung cancer, NSCLC generally demonstrates a slower rate of growth and progression. However, it may still metastasize beyond the lungs, particularly if not identified in earlier stages. Because early disease may not produce noticeable symptoms, diagnosis often occurs after the cancer has advanced. Clinical presentation, prognosis, and treatment options depend on factors such as tumor stage, histologic subtype, molecular characteristics, and overall patient health.

Types of Non-Small Cell Lung Cancer

NSCLC comprises several histologic subtypes, distinguished by the type of cells involved and their location within the lung:

  • Adenocarcinoma: The most common subtype, adenocarcinoma originates in glandular cells that line the alveoli and produce substances such as mucus. It is frequently observed in individuals with a history of smoking, though it also occurs in nonsmokers.
  • Squamous Cell Carcinoma: Also referred to as epidermoid carcinoma, this subtype arises from flat, thin cells that line the airways. It is often centrally located in the lungs and is strongly associated with tobacco exposure.
  • Large Cell Carcinoma: This category includes tumors composed of large, undifferentiated cells that may develop in various areas of the lung. Large cell carcinomas tend to grow and spread more rapidly than other NSCLC subtypes.

Less common variants include adenosquamous carcinoma, sarcomatoid carcinoma, salivary gland–type tumors, carcinoid tumors, and tumors that cannot be otherwise classified. Accurate classification is important for determining appropriate treatment strategies and evaluating potential molecular targets.

Risk Factors for Non-Small Cell Lung Cancer

A risk factor is any characteristic or exposure that increases the likelihood of developing a disease. While not all individuals with risk factors will develop NSCLC, understanding these factors can inform prevention and early detection strategies.

  • Tobacco Use: Cigarette smoking remains the most significant risk factor for NSCLC. Risk increases with earlier initiation, longer duration, and greater intensity of smoking. Use of cigars and pipes also contributes to risk.
  • Secondhand Smoke Exposure: Inhalation of smoke from others is associated with an increased likelihood of developing lung cancer.
  • Environmental and Occupational Exposures: Contact with carcinogenic substances such as asbestos, arsenic, chromium, beryllium, nickel, soot, or tar, particularly in workplace settings, can elevate risk.
  • Radiation Exposure: Prior radiation therapy to the chest, exposure to radon gas in homes or workplaces, and other sources of ionizing radiation may contribute to lung cancer development.
  • Air Pollution: Long-term exposure to polluted air has been associated with increased lung cancer risk.
  • Genetic and Medical Factors: A family history of lung cancer, advancing age, and certain underlying health conditions, including HIV infection, may increase susceptibility.
  • Other Contributing Factors: Use of beta carotene supplements in individuals who smoke has been associated with increased risk.

The presence of multiple risk factors may have a cumulative effect. However, individuals without recognized risk factors may still develop NSCLC, highlighting the importance of ongoing research, screening where appropriate, and risk-reduction strategies.

Sources: Cancer.gov and my.clevelandclinic.org

Related News from AMCP Daily Dose
Journal of Managed Care + Specialty Pharmacy Resources
JMCP | Journal of Managed Care Specialty Pharmacy
Free Access | Research Article |

Real-world costs, treatment patterns, and clinical outcomes associated with treatments for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer

Alectinib, brigatinib, and lorlatinib are all preferred first-line (1L) therapies for anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) in National Comprehensive Cancer Network (NCCN) guidelines. Although clinical trials have demonstrated their efficacy, real-world evidence on treatment patterns, costs, and outcomes may help differentiate these therapies and inform optimal 1L treatment selection in the absence of head-to-head comparisons.
JMCP | Journal of Managed Care Specialty Pharmacy
Free Access | Research Article |

Cost-effectiveness of cemiplimab plus chemotherapy vs pembrolizumab plus chemotherapy as first-line treatment for advanced non–small cell lung cancer

In 2022, the US Food and Drug Administration approved cemiplimab in combination with chemotherapy (CCT) as a first-line treatment for advanced non–small cell lung cancer (aNSCLC). However, whether CCT presents a cost-effective alternative to the previously preferred first-line treatment, pembrolizumab plus chemotherapy (PCT), remains uncertain.
JMCP | Journal of Managed Care Specialty Pharmacy
Free Access | Research Article |

Clinical and economic impact of recurrence in unresected non–small cell lung cancer treated with primary stereotactic body radiotherapy: A real-world study using SEER-Medicare data

Stereotactic body radiotherapy (SBRT) is the recommended treatment for inoperable, early-stage non–small cell lung cancer (NSCLC). Although prior research has assessed overall survival (OS) and recurrence rates post-SBRT, limited data exist on the clinical and economic impact of recurrence and the association between event-free survival (EFS) and OS in this patient population.
JMCP | Journal of Managed Care Specialty Pharmacy
Free Access | Research Article |

Cost-effectiveness models of non–small cell lung cancer: A systematic literature review

Non–small cell lung cancer (NSCLC) presents a formidable global health challenge owing to significant morbidity, high mortality rates, and substantial economic burden. Recent advances in targeted therapies and immunotherapies have transformed NSCLC treatment, but efficacy varies across patients. Tailoring treatment to patients can improve outcomes and potentially improve cost-effectiveness (ie, value for money) as well. For NSCLC, cost-effectiveness must often be estimated using economic modeling, and estimates are only as good as the models. Existing cost-effectiveness models are not necessarily suitable for evaluating personalized medicines
JMCP | Journal of Managed Care Specialty Pharmacy
Free Access | Research Article |

Comparative real-world survival of first-line atezolizumab, nivolumab, and pembrolizumab in older patients with metastatic non–small cell lung cancer

Although immune checkpoint inhibitors (ICIs) have significantly improved overall survival (OS) for patients with metastatic non–small cell lung cancer (mNSCLC), there is a paucity of comparative effectiveness evidence to inform optimal first-line treatment selection.
JMCP | Journal of Managed Care Specialty Pharmacy
Free Access | Research Article |

Cost-effectiveness of large-panel next-generation sequencing in guiding first-line treatment decisions for patients with nonsquamous advanced non–small cell lung cancer

Clinical practice guidelines recommend broad-panel genomic profiling to identify actionable genomic alterations for patients with advanced non–small cell lung cancer (aNSCLC).
JMCP | Journal of Managed Care Specialty Pharmacy
Free Access | Research Article |

Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non–small cell lung cancer

For patients with metastatic non–small cell lung cancer (mNSCLC), next-generation sequencing (NGS) biomarker testing has been associated with a faster time to appropriate targeted therapy and more comprehensive testing relative to polymerase chain reaction (PCR) testing. However, the impact on payer costs and clinical outcomes during patients’ treatment journeys has not been fully characterized.
JMCP | Journal of Managed Care Specialty Pharmacy
Free Access | Research Article |

Real-world clinical and economic outcomes for patients with advanced non–small cell lung cancer enrolled in a clinical trial following comprehensive genomic profiling via liquid biopsy

A common concern limiting coverage of CGP by payers is the potential of identifying biomarkers beyond guideline-recommended treatments, which creates a perception that insurance companies are being positioned to “pay for research.” However, these biomarkers can increase clinical trial eligibility, and specialty pharmacy management may have an interest in maximizing the clinical trial enrollment of members.
JMCP | Journal of Managed Care Specialty Pharmacy
Free Access | Research Article |

The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non–small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations

To estimate the budget impact, for a US health plan with 10 million members, of introducing mobocertinib for the treatment of patients with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations who have been previously treated with platinum-based chemotherapy.
JMCP | Journal of Managed Care Specialty Pharmacy
Free Access | Research Article |

Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non–small cell lung cancer

Intermediate endpoints, such as disease-free survival (DFS), have shown good correlation with overall survival (OS) in early-stage non–small cell lung cancer (NSCLC) clinical trials. However, real-world data are limited, and no previous real-world study has quantified the clinical and economic burden of disease recurrence.
JMCP | Journal of Managed Care Specialty Pharmacy
Free Access | Research Article |

Adverse event costs associated with first-line therapy for advanced non–small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint inhibitors

Immune checkpoint inhibitors, such as pembrolizumab, nivolumab, and atezolizumab, have demonstrated substantial survival benefits in patients with advanced non–small cell lung cancer (NSCLC). However, there is limited evidence on their relative safety profiles and adverse event (AE)–related cost burden.
JMCP | Journal of Managed Care Specialty Pharmacy
Free Access | Research Article |

The cost-effectiveness of brigatinib in adult patients with ALK inhibitor–naive ALK-positive non–small cell lung cancer from a US perspective

The discovery of specific oncogenic drivers in non–small cell lung cancer (NSCLC) has led to the development of highly targeted anaplastic lymphoma kinase tyrosine kinase inhibitors (ALKis). Brigatinib is a next-generation ALKi associated with prolonged progression-free survival in patients with ALKi-naive ALK+ NSCLC.
JMCP | Journal of Managed Care Specialty Pharmacy
Free Access | Research Article |

Real-world adherence and persistence with anaplastic lymphoma kinase inhibitors in non–small cell lung cancer

Lung cancer is the leading cause of cancer-related deaths in the United States. Several anaplastic lymphoma kinase (ALK) rearrangement inhibitors have been approved for the treatment of metastatic ALK-positive non–small cell lung cancer (NSCLC). Effective disease management requires an understanding of how these treatments are used in clinical practice, since low treatment adherence and/or early discontinuation have been associated with poor patient outcomes.